[go: up one dir, main page]

MX2010005008A - Metodos y composiciones para retardar aumento de peso asociado con el uso de farmacos anti-psicoticos atipicos. - Google Patents

Metodos y composiciones para retardar aumento de peso asociado con el uso de farmacos anti-psicoticos atipicos.

Info

Publication number
MX2010005008A
MX2010005008A MX2010005008A MX2010005008A MX2010005008A MX 2010005008 A MX2010005008 A MX 2010005008A MX 2010005008 A MX2010005008 A MX 2010005008A MX 2010005008 A MX2010005008 A MX 2010005008A MX 2010005008 A MX2010005008 A MX 2010005008A
Authority
MX
Mexico
Prior art keywords
atypical antipsychotic
antipsychotic drugs
compositions
methods
dopamine agonist
Prior art date
Application number
MX2010005008A
Other languages
English (en)
Inventor
Diane Mcintosh
Kevin Kjernisted
Original Assignee
Diane Mcintosh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diane Mcintosh filed Critical Diane Mcintosh
Publication of MX2010005008A publication Critical patent/MX2010005008A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen métodos y composiciones para prevenir o reducir aumento de peso y síndrome metabólico asociado en pacientes que reciben fármacos anti-psicóticos atípicos para el tratamiento de enfermedad mental. La invención comprende administrar a un paciente que necesita tratamiento de una cantidad efectiva de un agonista de dopamina junto con una cantidad efectiva de un fármaco anti-psicótico atípico. En una modalidad de la invención, el agonista de dopamina es pramipexol. El agonista de dopamina puede administrarse en una baja dosis, tal como menos de 1 mg al día de pramipexol. Ejemplos de fármacos anti-psicóticos atípicos que pueden administrarse junto con el agonista de dopamina incluyen clozapina, olanzapina, quetiapina y risperadona.
MX2010005008A 2007-11-05 2008-11-05 Metodos y composiciones para retardar aumento de peso asociado con el uso de farmacos anti-psicoticos atipicos. MX2010005008A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98556307P 2007-11-05 2007-11-05
PCT/CA2008/001962 WO2009059418A1 (en) 2007-11-05 2008-11-05 Methods and compositions for retarding weight gain associated with use of atypical antipsychotic drugs

Publications (1)

Publication Number Publication Date
MX2010005008A true MX2010005008A (es) 2010-07-30

Family

ID=40620883

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005008A MX2010005008A (es) 2007-11-05 2008-11-05 Metodos y composiciones para retardar aumento de peso asociado con el uso de farmacos anti-psicoticos atipicos.

Country Status (15)

Country Link
US (1) US20100311717A1 (es)
EP (2) EP2214671B1 (es)
JP (1) JP5433581B2 (es)
KR (1) KR20100075678A (es)
CN (2) CN101888844A (es)
AU (1) AU2008324674A1 (es)
BR (1) BRPI0820573A2 (es)
CA (1) CA2622696A1 (es)
EA (1) EA020739B1 (es)
IL (1) IL205538A0 (es)
MX (1) MX2010005008A (es)
NZ (1) NZ585621A (es)
UA (1) UA103756C2 (es)
WO (1) WO2009059418A1 (es)
ZA (1) ZA201003701B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014199935A1 (ja) * 2013-06-10 2014-12-18 株式会社エム・エス・エス 小胞体ストレスシグナルを抑制することによる，薬剤の副作用としての体重増加や肥満を防止するために用いられる肥満防止剤
CA2917702A1 (en) * 2013-07-18 2015-01-22 Jazz Pharmaceuticals International Iii Limited Treatment for obesity
MA48477A (fr) 2017-04-24 2020-03-04 Chase Therapeutics Corp Compositions et méthodes de traitement de la dépression
CN109939112A (zh) * 2019-05-10 2019-06-28 辽宁大学 利培酮在制备降血脂药物中的应用
IL291775A (en) 2019-12-11 2022-06-01 Corcept Therapeutics Inc Methods for the treatment of obesity caused by antipsychotic treatment using Miricurilent
BR112022022845A2 (pt) 2020-05-09 2022-12-13 Shenzhen Profound View Pharmaceutical Tech Co Ltd Tratamento de efeitos adversos causados por antipsicóticos atípicos
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
AU4973800A (en) * 1999-06-09 2000-12-28 Eli Lilly And Company Combination for treating weight gain associated with antipsychotic use comprising an atypical antipsychotic and an h2 antagonist
WO2002019998A2 (en) * 2000-09-08 2002-03-14 Eli Lilly And Company A method of treating weight gain associated with atypical antipsychotic use
CA2445650A1 (en) * 2001-05-25 2002-12-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Combination of a dopamine d2-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways
DE10148233A1 (de) * 2001-09-28 2003-04-10 Boehringer Ingelheim Pharma Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
US20050054652A1 (en) * 2002-07-29 2005-03-10 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US20040077679A1 (en) * 2002-07-29 2004-04-22 Cincotta Anthony H. Therapeutic treatment for the metabolic syndrome and type 2 diabetes
US20040266794A1 (en) * 2003-03-21 2004-12-30 Boehringer Ingelheim International Gmbh Pramipexole for the reduction of excessive food intake for children
US8323158B2 (en) * 2003-06-27 2012-12-04 Keiser Corporation Exercise apparatus using weight and pneumatic resistances
EP1734955A2 (en) * 2004-01-13 2006-12-27 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weigt loss
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US20070015763A1 (en) * 2005-07-12 2007-01-18 Pfizer Inc Treatment of psychosis associated with parkinson's disease and subcortical dementias using a combination of an atypical antipsychotic with a dopamine agonist

Also Published As

Publication number Publication date
JP5433581B2 (ja) 2014-03-05
EP2214671A1 (en) 2010-08-11
US20100311717A1 (en) 2010-12-09
JP2011502175A (ja) 2011-01-20
ZA201003701B (en) 2012-01-25
BRPI0820573A2 (pt) 2015-06-16
KR20100075678A (ko) 2010-07-02
UA103756C2 (ru) 2013-11-25
EP2772256A1 (en) 2014-09-03
EP2214671B1 (en) 2014-05-14
EP2214671A4 (en) 2011-10-12
CN104069498A (zh) 2014-10-01
IL205538A0 (en) 2010-12-30
EA020739B1 (ru) 2015-01-30
AU2008324674A1 (en) 2009-05-14
CA2622696A1 (en) 2009-05-05
WO2009059418A1 (en) 2009-05-14
CN101888844A (zh) 2010-11-17
EA201070557A1 (ru) 2010-10-29
NZ585621A (en) 2013-04-26

Similar Documents

Publication Publication Date Title
UA103756C2 (ru) Способы замедления набора веса, связанного с применением атипичных антипсихотических лекарственных средств
MY159353A (en) Pirfenidone treatment for patients with atypical liver function
EP2216024A3 (en) Use of Ranolazine for the treatment of cardiovascular diseases
IL203747A (en) Use of a steroid sex precursor in the manufacture of a 13mg dose or less for daily dosing through the vagina to treat vaginal diseases and a vaginal pharmacological preparation containing it
JP2013505282A5 (es)
NZ593461A (en) Exendin for treating diabetes and reducing body weight
NZ605888A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
MX2011013902A (es) Tratamiento de esclerosis multiple con laquinimod.
CO6361944A2 (es) Combinacion de una insulina y un agonista de glp-1
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
NZ588913A (en) Liver cancer drug
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
UA105191C2 (ru) Лечение пирфенидоном пациентов с атипической функцией печени
MX2013011174A (es) Prevencion de hipoglucemia en pacientes con diabetes sacarina de tipo 2.
NZ595376A (en) Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration
IN2014DN08582A (es)
NZ630494A (en) Administration of lorcaserin to individuals with renal impairment
IL179896A (en) Opioid with a delayed oral dosage form containing a mixture of opioid agonist and antagonist for use in the treatment of nervous leg syndrome
IL194500A0 (en) Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
TW200501946A (en) Pharmaceutical composition for the treatment of schizophrenia in a patient with overweight
Englisch et al. Bupropion for depression in schizophrenia
UA108980C2 (en) APPLICATION OF DONEDARONE FOR THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATIONS
IL173822A0 (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep

Legal Events

Date Code Title Description
FG Grant or registration